The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...
The U.S. health regulator has approved GSK's add-on drug to treat severe asthma, the drugmaker said on Tuesday, paving the ...
LONDON (Reuters) - In January, GlaxoSmithKline's new head of pharmaceuticals Luke Miels issued a blunt challenge to his managers: find budget savings of 20 percent. The plan was to pool the savings ...
GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
GlaxoSmithKline is cutting off commercial CME providers, following Pfizer’s lead. GSK said starting next year, it will fund only “independent” CME programs designed to close gaps in patient care, and ...
GlaxoSmithKline is buying Human Genome Sciences for $3.6 billion, giving it full ownership of Benlysta, along with albiglutide and darapladib, after months of M&A intrigue. “We are pleased to have ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback